(TCHP) T. Rowe Price Blue Chip - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US87283Q1076

TCHP: Blue-Chip, Growth, Companies, Securities, Large-Cap

The fund primarily invests at least 80% of its net assets in securities of blue-chip companies with growth characteristics, focusing on established firms with strong market positions, seasoned management, and robust financials. As a non-diversified fund, it may concentrate its holdings in a smaller number of high-conviction investments, potentially including sectors with high growth prospects such as technology or healthcare.

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of blue-chip companies with growth characteristics. Blue-chip growth companies are firms that, in the investment advisers view, are well established in their industries and have the potential for above-average earnings growth. It focuses on companies with leading market positions, seasoned management, and strong financial fundamentals. The fund is non-diversified.

T. Rowe Price Blue Chip Growth ETF (TCHP) is designed to capture the growth potential of established companies with strong fundamentals. The funds investment strategy emphasizes companies with leading market positions, experienced management teams, and robust financial health, which are key indicators of sustainable growth. As a non-diversified fund, it may have a more concentrated portfolio, which can lead to higher volatility but also offers the potential for greater returns.

Based on the technical and fundamental data, the funds recent price of 40.06 is above its 20-day and 50-day moving averages but slightly below its 200-day moving average, suggesting a potential consolidation phase. The average trading volume of 218,153 shares over the past 20 days indicates moderate liquidity. The ATR of 1.34 points to relatively stable price movements, with a narrow range of price fluctuations expected in the near term. The funds assets under management (AUM) of $1.035 billion reflect its popularity among investors seeking exposure to large-cap growth companies.

Additional Sources for TCHP ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

TCHP ETF Overview

Market Cap in USD 1,307m
Category Large Growth
TER 0.57%
IPO / Inception 2020-08-04

TCHP ETF Ratings

Growth Rating 48.0
Fundamental -
Dividend Rating 1.0
Rel. Strength 1.52
Analysts -
Fair Price Momentum 39.16 USD
Fair Price DCF -

TCHP Dividends

Currently no dividends paid

TCHP Growth Ratios

Growth Correlation 3m 78.6%
Growth Correlation 12m 37.6%
Growth Correlation 5y 53.6%
CAGR 5y 11.61%
CAGR/Max DD 5y 0.27
Sharpe Ratio 12m 1.32
Alpha -1.05
Beta 1.239
Volatility 14.42%
Current Volume 65.4k
Average Volume 20d 88.7k
What is the price of TCHP shares?
As of June 16, 2025, the stock is trading at USD 43.03 with a total of 65,414 shares traded.
Over the past week, the price has changed by -1.28%, over one month by +1.89%, over three months by +10.39% and over the past year by +10.96%.
Is T. Rowe Price Blue Chip a good stock to buy?
Partly, yes. Based on ValueRay´s Analyses, T. Rowe Price Blue Chip (NYSE ARCA:TCHP) is currently (June 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 47.98 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TCHP is around 39.16 USD . This means that TCHP is currently overvalued and has a potential downside of -8.99%.
Is TCHP a buy, sell or hold?
T. Rowe Price Blue Chip has no consensus analysts rating.
What are the forecasts for TCHP share price target?
According to our own proprietary Forecast Model, TCHP T. Rowe Price Blue Chip will be worth about 45.5 in June 2026. The stock is currently trading at 43.03. This means that the stock has a potential upside of +5.65%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 45.5 5.6%